Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15307MR)

This product GTTS-WQ15307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3810MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ13079MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ6597MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ788MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ2574MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ2609MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ8101MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ9278MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW